Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICER Followed by Zevalin in Relapsed/Refractory B-Cell Lymphoma
NCT00193505Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 2003
- Primary completion
- Aug 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma, sponsored by SCRI Development Innovations. Primary endpoint: Complete Response Rate. Started Oct 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00193505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193505.